The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myelomaAndrew Spencer, Christine Chen, Deborah A. Smith et al.|Blood|2014Cited by 140
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).María‐Victoria Mateos, Vânia Hungria, Paweł Robak et al.|Journal of Clinical Oncology|2024Cited by 21